Striving to cure adult T-cell leukaemia/lymphoma: A role for allogeneic stem cell transplant

Simple item page
dc.contributor.authorPhillips, Elizabeth H.
dc.contributor.authorHodson, Andrew
dc.contributor.authorHermine, Olivier
dc.contributor.authorBazarbachi, Ali Abdul Hamid
dc.contributor.authorCwynarski, Kate
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:48:38Z
dc.date.available2025-01-24T11:48:38Z
dc.date.issued2016
dc.description.abstractAdult T-cell leukaemia/lymphoma (ATL) is an aggressive HTLV-1-related malignancy, rare outside of regions where the retrovirus is endemic. Although the use of antiviral therapy has improved outcomes, particularly for indolent forms of ATL, response to combination chemotherapy is poor and outcomes for aggressive subtypes remains dismal. Consolidation with allogeneic stem cell transplant (alloSCT) has an increasing role in the management of ATL in eligible patients, offering favourable long-term remission rates. However, relatively high-transplant-related mortality and issues with donor recruitment for certain ethnicities remain problematic. In this review, we discuss the rationale for and issues surrounding alloSCT in ATL in the context of conventional and emerging therapies. © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
dc.identifier.doihttps://doi.org/10.1038/bmt.2016.154
dc.identifier.eid2-s2.0-84987625219
dc.identifier.pmid27618683
dc.identifier.urihttp://hdl.handle.net/10938/30831
dc.language.isoen
dc.publisherNature Publishing Group
dc.relation.ispartofBone Marrow Transplantation
dc.sourceScopus
dc.subjectAdult
dc.subjectCombined modality therapy
dc.subjectHuman t-lymphotropic virus 1
dc.subjectHumans
dc.subjectLeukemia-lymphoma, adult t-cell
dc.subjectStem cell transplantation
dc.subjectTreatment outcome
dc.subjectAlemtuzumab
dc.subjectArsenic trioxide
dc.subjectBortezomib
dc.subjectDaclizumab
dc.subjectLenalidomide
dc.subjectMogamulizumab
dc.subjectRecombinant alpha interferon
dc.subjectZidovudine
dc.subjectAllogeneic stem cell transplantation
dc.subjectAntiviral therapy
dc.subjectAutologous hematopoietic stem cell transplantation
dc.subjectCancer chemotherapy
dc.subjectCancer prognosis
dc.subjectCord blood stem cell transplantation
dc.subjectCytomegalovirus infection
dc.subjectDonor selection
dc.subjectEngraftment
dc.subjectGraft failure
dc.subjectGraft recipient
dc.subjectGraft versus host reaction
dc.subjectGraft versus leukemia effect
dc.subjectHtlv-1 infection
dc.subjectHuman
dc.subjectImmunosuppressive treatment
dc.subjectInfectious complication
dc.subjectMaintenance chemotherapy
dc.subjectMinimal residual disease
dc.subjectOutcome assessment
dc.subjectOverall survival
dc.subjectPhase 2 clinical trial (topic)
dc.subjectPhase 3 clinical trial (topic)
dc.subjectPriority journal
dc.subjectProgression free survival
dc.subjectRandomized controlled trial (topic)
dc.subjectReview
dc.subjectSurvival time
dc.subjectT cell depletion
dc.subjectT cell leukemia
dc.subjectTransplantation conditioning
dc.subjectTreatment response
dc.subjectViral clearance
dc.subjectDrug effects
dc.subjectMortality
dc.subjectMultimodality cancer therapy
dc.subjectProcedures
dc.titleStriving to cure adult T-cell leukaemia/lymphoma: A role for allogeneic stem cell transplant
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2016-9202.pdf
Size:
195.45 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine